ALDG2 - Overview: Autoimmune Liver Disease Panel, Serum
Evaluating patients with suspected autoimmune liver disease, specifically autoimmune hepatitis or primary biliary cholangitis Evaluating patients with liver disease of unknown etiology
PTH2 - Overview: Parathyroid Hormone, Serum
Diagnosis and differential diagnosis of hypercalcemia Diagnosis of primary, secondary, and tertiary hyperparathyroidism Diagnosis of hypoparathyroidism Monitoring kidney failure patients for possible renal osteodystrophy
PUPYU - Overview: Purines and Pyrimidines Panel, Random, Urine
Evaluating patients with symptoms suspicious for disorders of purine and pyrimidine metabolism Monitoring patients with disorders of purine and pyrimidine metabolism Laboratory evaluation of primary and secondary hyperuricemias
EM - Overview: Electron Microscopy, Varies
Providing information to aid in the diagnosis of medical disorders such as storage diseases, CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), and primary ciliary dyskinesia
AN3TS - Overview: Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Serum
Evaluating patients who present with a subacute neurological disorder of undetermined etiology and have risk factors for primary lung carcinoma Reporting an end titer result from serum specimens
CARNS - Overview: Carnitine, Serum
Evaluation of patients with a clinical suspicion of a wide range of conditions including organic acidemias, fatty acid oxidation disorders, and primary carnitine deficiency using serum specimens
CARN - Overview: Carnitine, Plasma
Evaluation of patients with a clinical suspicion of a wide range of conditions including organic acidemias, fatty acid oxidation disorders, and primary carnitine deficiency using plasma specimens
ROXUR - Overview: Oxalate, Random, Urine
Monitoring therapy for kidney stones using random urine specimens Identifying increased urinary oxalate as a risk factor for stone formation Diagnosis of primary or secondary hyperoxaluria
AN3TC - Overview: Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Spinal Fluid
Evaluating patients who present with a subacute neurological disorder of undetermined etiology and have risk factors for primary lung carcinoma Reporting an end titer result from cerebrospinal fluid specimens
POXA1 - Overview: Oxalate, Plasma
Assessing the body pool size of oxalate in patients with enzyme deficiencies, such as primary hyperoxaluria (PH), or patients with enteric hyperoxaluria Aiding in the diagnosis of PH in a patient with chronic kidney disease of...
Primary ciliary dyskinesia - Insights
Learn more about Mayo Clinic Laboratories’ robust approach to testing for primary ciliary dyskinesia, a rare genetic condition that can lead to chronic otosinopulmonary disease and infertility in men....
CPT Codes and LOINC Update: September 2019 - Insights
View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of September 2019....
https://www.mayocliniclabs.com/it-mmfiles/cpt-code-changes.xlsx
note, CPT Code changes listed on this document are effective January 1st, 2025.*** ***Updates and other changes may occur, and be reflected on this document, leading up to 2025*** ***CPT Code Updates...
MCL Primary Ciliary Dyskinesia Genetic Testing Patient Information MC1235297
MCL Primary Ciliary Dyskinesia Genetic Testing Patient Information Complete print Reset Form Primary Ciliary Dyskinesia Genetic Testing Patient Information Instructions Accurate interpretation reporting...
New communication process for CPT Code changes - Insights
Mayo Clinic Laboratories (MCL) is pleased to announce an essential update to our CPT code communication process and website layout. This change is designed to bring timely notifications for accurate billing...